13 Dec, 2021 New Results from Phase 1 Study of Cemdisiran + Pozelimab Presented at ASH Annual Meeting 2021
New results from a Phase 1 study of cemdisiran in combination with pozelimab in healthy volunteers, in collaboration with Regeneron, were presented at the 63rd American Society of Hematology (ASH) Annual Meeting, held December 11-14, 2021.